Home > Insider Trading > Filing (0001209191-20-007674)

Filing Details

Accession Number:: 0001209191-20-007674
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-02-07 18:37:35
Reporting Period:: 2020-02-05

Accepted Time:: 2020-02-07 18:37:35
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
914475	Neurocrine Biosciences Inc	NBIX	Biological Products, (No Disgnostic Substances) (2836)	330525145

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1423837	P. Haig Bozigian	12780 El Camino Real San Diego CA 92130	Chief Development Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2020-02-05	1,342	$103.00	143,292	No	4	S	Direct
Common Stock	Disposition	2020-02-05	704	$103.06	143,925	No	4	S	Direct
Common Stock	Disposition	2020-02-06	1,395	$101.56	145,180	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option	Acquisiton	2020-02-06	15,337	$0.00	15,337	$102.90
Common Stock	Restricted Stock Unit	Acquisiton	2020-02-06	2,430	$0.00	2,430	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
15,337	2021-02-06	2030-02-06	No	4	A	Direct
2,430			No	4	A	Direct

Footnotes

Sale of 1,342 shares of common stock issued upon vesting of 2,550 restricted stock units on February 5, 2020 to cover payroll and withholding taxes, with the balance of the shares (1,208) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $101.85 to $105.19. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Includes a total of 108 shares acquired under the Neurocrine Biosciences 2018 Employee Stock Purchase Plan on August 30, 2019.
Sale of 704 shares of common stock issued upon vesting of 1,337 restricted stock units on February 5, 2020 to cover payroll and withholding taxes, with the balance of the shares (633) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $101.90 to $104.13. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Sale of 1,395 shares of common stock issued upon vesting of 2,650 restricted stock units on February 6, 2020 to cover payroll and withholding taxes, with the balance of the shares (1,255) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $100.12 to $103.08. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Represents option which vests in full on February 6, 2021.
Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock.
The Restricted Stock Units vests in full on February 6, 2021.